GRAIL Inc. (GRAL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 15 | 56 | 93 | 126 | 147 | 165 | 181 |
| Operating profit | $m | -534 | -559 | ||||||
| Net profit | $m | -312 | -1,248 | -5,399 | -1,466 | -2,027 | -408 | -392 | -355 |
| EPS reported | $ | -11.11 | -9.75 | ||||||
| Operating cashflow per share | $ | -8.14 | -6.84 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -8.14 | -6.85 | ||||||
| Free cash flow | $m | -299 | -295 | ||||||
| Net debt | $m | -850 | -862 | ||||||
| Book value equity | $m | 2,578 | 2,543 | ||||||
| Book value per share | $ | 70.14 | 58.98 | ||||||
| Number of shares | m | 36.75 | 43.11 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.22 | 1.24 | ||||||
| P/S LTM | x | 21.37 | 19.03 | ||||||
| P/FCF LTM | x | -10.52 | -10.65 | ||||||
| EV/EBITDA LTM | x | -7.92 | -7.25 | ||||||
| EV/Sales LTM | x | 20.34 | 17.84 | ||||||
| Earnings Yield LTM | % | -12.98% | -13.38% | ||||||
| FCF Yield | % | -9.51% | -9.39% | ||||||
| Quality | |||||||||
| ROE | % | -15.84% | -15.88% | ||||||
| ROIC | % | -14.30% | -14.93% | ||||||
| Operating margin | % | -3.63% | -3.38% | ||||||
| Gross margin | % | -42.52% | -10.83% | ||||||
| FCF/Sales | % | -203.17% | -178.66% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +17.18% | +31.58% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.05 | -3.23 | ||||||
| Net Debt/EBITDA | x | 0.40 | -0.09 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +1.74% | 0.00% | ||||||
| Net debt/Equity | x | -0.33 | -0.34 | ||||||
| Gross debt/equity | x | 0.04 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free